Home » Newsletters » BioWorld Science

BioWorld Science

June 12, 2002

View Archived Issues

SignalGene and Novuspharma enter collaboration and option agreement for SG-292

Novel prenyltranferase inhibitors useful in cancer therapy identified at Merck

New 5-HT6 antagonists for obesity and CNS disorders

Lilly presents novel glutamate receptor function enhancers

Protein kinase inhibitors in development at Morphochem

Nucleoside analogues and their use in viral infections and cancer

COX-2 inhibitors claimed by researchers at Temple University

CCR1 antagonists in early development at Pfizer

Isradipine safely reduces cocaine-related effects

Carrier-mediated active transport is responsible for hepatic uptake of Z-335

Alexion reviews third-quarter highlights

Positive phase III results announced for ophthalmic implant for diabetic macular edema

Roche Diagnostics acquires HPV patent portfolio from Institut Pasteur

GSK to evaluate BioVex's ImmunoVEX vaccine platform

ActivX and Kyorin enter drug discovery collaboration in type 2 diabetes

Clinical results for oral tridentate iron chelator ICL-670 discussed in Florence

Adenovirus-mediated ribonucleotide reductase gene therapy inhibits human colon cancer growth

TranzVector-mediated delivery of human IFNbeta gene effective in human tumor xenograft model

GVAX cancer vaccines highlighted at the ASGT meeting

Antiproliferative sulindac derivative targets the Ras pathway

New antimicrobial peptide may be useful for burn and wound infections

Adherex Technologies updates Exherin progress

Lexicon Genetics identifies new target for obesity drug development

Promising results reported for Trisenox in myelodysplastic syndromes

Transkaryotic Therapies broadens intellectual property in Gaucher's and Fabry's diseases

Wyeth discontinues development of PTP-112

Merck & Co. to refile Arcoxia NDA in second half of 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.